01 — At a Glance
The Sleeper Specialty Fats Play That Just Woke Up
- 52-Week High / Low₹1,774 / ₹850
- FY26 TTM Revenue₹1,208 Cr
- FY26 TTM PAT₹216 Cr
- TTM EPS₹36.19
- Q3 EPS (₹)₹11.43
- Book Value₹95.6
- Price to Book13.4x
- Debt / Equity0.66x
- Interest Coverage8.21x
- QIP Board Approval₹500 Cr
Auditor’s Note: This is not a boring commodity play dressed up as a specialty fats story. Manorama has posted 73% YoY revenue growth, 131% profit growth, and a 27.1% EBITDA margin in Q3. The stock trades at 35.2x P/E — expensive by traditional standards, but potentially cheap if management executes a ₹460 crore capex blitz to build cocoa butter alternatives, extraction capacity, and West African sourcing. The board just green-lit a ₹500 crore QIP to fund the party. Translation: India’s best-kept secret in specialty fats is about to become much less secret.
02 — Introduction
Welcome to the Specialty Fats Circus. Or: How I Learned to Stop Worrying and Love Cocoa Butter Equivalents
Manorama Industries manufactures specialty fats and butters from exotic seeds and nuts — primarily sal, mango, and shea. Groundbreaking stuff? Not really. But listen: this company is a global monopoly in sal and mango-based cocoa butter equivalents. It supplies Ferrero, Mondelez, Nestlé, Hershey’s, and The Body Shop. Seventy-three percent of revenues come from exports. The business model is called “Waste to Wealth” — they source tree-borne seeds that nobody else bothers with, refine them, and sell specialised fats to chocolate and cosmetics manufacturers worldwide.
For years, Manorama was a quiet compounder. 19% sales CAGR over 10 years. Boring. Dull. The kind of company that makes money while you’re not watching.
Then, in July 2024, they commissioned a new 25,000 MTPA fractionation capacity. Suddenly, the operating leverage kicked in. Q3 FY26 delivered the highest revenue in company history. Profit growth hit 131%. Margins stabilised at 27%. And the board just approved a ₹500 crore QIP to fund ₹460 crore worth of capex over 2–3 years. The thesis: build cocoa butter alternatives, extract more seeds in-house, integrate backward to West Africa, and scale from a ₹1,200 crore revenue company to something substantially larger. If they pull it off, the valuation math changes. If they don’t, well — investors will pay 35x for the right to find out.
Concall Gold (Jan 2026): Management stated: “Our CBE fats and butters are developed through specialized fat blending and fractionation… our prices are not directly related to any commodity cycles.” Translation: this is not cocoa. This is technology. This is why a specialty fats company can charge meaningful premiums even when cocoa prices implode.
03 — Business Model: WTF Do They Even Do?
Tree Nuts Meet Chocolate Labs. Alchemy Ensues.
Manorama procures sal seeds (from Odisha, Chhattisgarh, Jharkhand), mango kernels (from across India’s sal forests), and shea nuts (from West Africa). These are sourced from 18,000+ collection centres across India and from rural women co-operatives and tribal networks in West Africa. Free feedstock? Not quite. But cheap, underutilised, and abundant.
The company then runs these through integrated plants — extraction, refining, fractionation, blending, and packing — all housed at Birkoni, Chhattisgarh, and now distributed via 6 African subsidiaries. The output: cocoa butter equivalents (CBE), stearin, oils, and specialty butters. Seventy-five percent of sales now come from value-added products (stearin, CBE); 25% from lower-margin by-products (de-oiled cakes, fatty acids). The business model improves over time because by-products scale less than primary products.
Customers are global chocolate, confectionery, and cosmetics brands. Product approval is stringent, multi-year, and essentially irreplaceable once granted. This creates customer stickiness and pricing power — the classic moat that nobody notices until margins surprise to the upside.
Value-Added Mix (FY26)~75%Trending to 90–95%
CBE Share of Sales~30%Premium segment
Export Revenue73%9M FY26
Fractionation Cap (Now)40,000 MTPAFrom 15k pre-2024
Working Capital Alert: Management says the new ESOS/CBA product lines (coming via the ₹460 crore capex) will require only 1–2 months of working capital vs. the current ~5–6 months for the traditional model. Why? Because they’ll use captive olein (a byproduct from their own refining) instead of sourcing raw seeds. This could be the unspoken upside in the capex thesis.
💬 Have you ever checked what’s in the cocoa spread you buy at the grocery store? There’s a 40% chance it’s Manorama’s CBE. Do you feel special now?
04 — Financials Overview
Q3 FY26: The Numbers That Made Everyone Sit Up
